fda warning letters compounded semaglutide 2025 warns against GLP-1 medications FDA unleashes warning letters to

If youre kale-shy, this is a gentle entry point

This supports a model in which GLP-1RAs may exert direct plaque-modifying effects, although definitive human plaque-level confirmation remains limited

Zhang L, Naiki Y, Chang YT, Haider A, Copeland K, Lustig R, Morgan G, Mowat D, Moll G, Schwartz ID, Pang S: An update to define the hormonal criteria for inherited severe and mild 3-hydroxysteroid dehydrogenase (3-HSD) deficiency disorder and hormonal expression in carriers for 3-HSD deficiency

But since we dont know the cause, were more or less stuck with that second inflammation-reducing option: muting signaling proteins that channel inflammatory cells to injured tissues

Sinha VR, Trehan A